Bio Medica Laboratories financials and balance sheet

NSE: BMLLPharmaceuticals & Biotechnology

Last close ₹149.75down ₹5.25 (3.39%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹155.00.

Range of traded prices from listing on 29 May 2026 to 23 Oct 2026
₹101.50Low, 3 Jun 2026₹181.00High, 4 Sep 2026
Market cap
₹188 Cr
P/E
16.1
P/B
Shares changed
Dividend yield
Nonesince listing in May 2026
ROE
44.2%
Debt to equity
0.87
Volume, NSE
50,000100.0% delivered

1 year at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Bio Medica Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue43
  2. Materials and goods−17
  3. Employee costs−3.1
  4. Other expenses−2.9
  5. Operating profit20
  6. Depreciation−1.2
  7. Other income0.0
  8. Finance costs−2.3
  9. Profit before tax16
  10. Tax−4.4
  11. Net profit12

What the company owns

  • Inventory₹36 Cr
  • Plant, investments and other assets₹26 Cr
  • Receivables₹11 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Borrowings₹40 Cr
  • Net worth₹20 Cr
  • Other liabilities₹7 Cr
  • Owed to suppliers₹6 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Bio Medica Laboratories half-yearly results

₹ croreMar 2026Filed 27 Jul
Revenue from operations43.1
23.4
Materials and goods bought17.5
Employee costs3.1
Other expenses2.9
Operating profit before depreciation19.7
Operating margin45.6%
Materials, % of revenue40.6%
Employee costs, % of revenue7.1%
Other expenses, % of revenue6.7%
Depreciation and amortisation1.2
Operating profit after depreciation18.5
Other income0.0
Finance costs2.3
Profit before tax16.3
4.4
Net profit11.8
Net margin27.3%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2026Filed 27 Jul
20.3
26.5
Share capital9.2
Reserves17.3
Belonging to outside owners of subsidiaries−6.2
40.0
19.2
33.8
Total assets73.3
18.6
54.7
Net debt39.9
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2026Filed 27 Jul
−6.0
−3.5
−23.2
Receivables−6.5
Inventories−17.9
Payables−0.1
Other working capital1.3
Tax paid−4.2
Capital spending2.8
Free cash flow−8.8
Cash from investing−2.1
8.2
Dividends paid0.0
Shares issued0.0
Net change in cash0.1
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2026Filed 27 Jul
Earnings per share₹12.95
Diluted earnings per share₹12.95
Book value per share₹28.88

Ratios

Consolidated, years to March.Bio Medica Laboratories PE ratio and valuation

RatioMar 2026Filed 27 Jul
Return on equity44.4%
Return on capital employed30.6%
Cash conversion−51.2%
Interest cover8.2
Debt to equity1.97
Receivable days92
Inventory days759
Payable days116
Cash conversion cycle, days735
Working capital days371
Asset turnover0.59
Assets per rupee of net worth2.76
Sales per rupee of plant4.19
Capital spending to depreciation2.42

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
16.1%
Cash from operations against operating profit
−30.7%

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−6.0
Cash from investing−2.1
Cash from financing8.2
Capital spending2.8
Dividends paid0.0
Shares issued for cash0.0
Borrowings raised10.5
Borrowings repaid0.0

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Effective tax ratePublished threshold 17.16 per cent26.87
Tax charged less tax paid, % of profitOur threshold 10 percentage points1.07
A threshold marked as ours has no published figure; it is the line we read the check against.